Compare LUNR & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUNR | IMNM |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | 525 | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | 2021 | 2020 |
| Metric | LUNR | IMNM |
|---|---|---|
| Price | $14.00 | $23.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | $22.35 | ★ $32.80 |
| AVG Volume (30 Days) | ★ 5.6M | 790.2K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.23 | 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $210,059,000.00 | $6,941,000.00 |
| Revenue This Year | $343.00 | N/A |
| Revenue Next Year | $16.81 | $1,127.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.78 | $9.36 |
| 52 Week High | $46.75 | $30.06 |
| Indicator | LUNR | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 40.54 | 36.10 |
| Support Level | $12.70 | $19.03 |
| Resistance Level | $16.03 | $25.07 |
| Average True Range (ATR) | 0.77 | 1.01 |
| MACD | -0.09 | -0.52 |
| Stochastic Oscillator | 15.31 | 5.26 |
Intuitive Machines Inc is a space infrastructure and services company focused on enabling sustained human activity beyond Earth. It designs, builds, integrates, and operates space systems, offering infrastructure-as-a-service across low Earth orbit, geostationary orbit, cislunar space, and deep space. Its capabilities include spacecraft development and space-based network connectivity, serving commercial, civil, and national security customers. The company conducts sales both directly and through an extensive customer and partner network spanning North America, South America, Europe, Asia, and Australia, including rideshare delivery providers, lunar surface mobility providers, payload providers, communication satellite providers, and ground segment providers.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.